| case report | Q2782326 |
| scholarly article | Q13442814 |
| P2093 | author name string | Brigitte Maes | |
| Karin Pat | |||
| Jokke Wynants | |||
| Kristof Cuppens | |||
| Mike Ralki | |||
| P2860 | cites work | Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. | Q27851719 |
| Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort | Q27853282 | ||
| Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives | Q28289431 | ||
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | Q36221780 | ||
| Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. | Q47213006 | ||
| Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. | Q50146512 | ||
| Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring S310Y mutation: a case report | Q60307729 | ||
| HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer | Q83994832 | ||
| Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation | Q88119092 | ||
| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial | Q89496320 | ||
| P433 | issue | 2 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 625-630 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | Case reports in oncology | Q27722654 |
| P1476 | title | Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC | |
| P478 | volume | 12 |
| Q99582979 | Alternative splicing of HER2: a novel mediator of EGFR TKI resistance | cites work | P2860 |
Search more.